| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/26/2022 | 153.1% | HC Wainwright & Co. | $2 → $1 | Maintains | Buy |
| 08/16/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 08/16/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 08/15/2022 | 406.2% | BMO Capital | $6 → $2 | Maintains | Outperform |
| 08/12/2022 | 406.2% | Piper Sandler | $6 → $2 | Downgrades | Overweight → Neutral |
| 08/05/2022 | 659.3% | SVB Leerink | $4 → $3 | Maintains | Outperform |
| 05/19/2022 | 1418.6% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 04/21/2022 | 912.4% | SVB Leerink | $10 → $4 | Maintains | Outperform |
| 04/14/2022 | 406.2% | HC Wainwright & Co. | $8 → $2 | Maintains | Buy |
| 04/08/2022 | 1165.5% | Truist Securities | $12 → $5 | Maintains | Buy |
| 04/08/2022 | 1165.5% | Cantor Fitzgerald | $11 → $5 | Maintains | Overweight |
| 12/20/2021 | 2431% | SVB Leerink | $12 → $10 | Maintains | Outperform |
| 01/29/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/19/2020 | 1924.8% | HC Wainwright & Co. | $7 → $8 | Maintains | Buy |
| 11/13/2020 | 2937.21% | SVB Leerink | $14 → $12 | Maintains | Outperform |
| 10/28/2020 | 2937.21% | Cantor Fitzgerald | $9 → $12 | Maintains | Overweight |
| 10/27/2020 | 2431% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 05/08/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 04/29/2020 | 1671.7% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 11/13/2019 | 3190.31% | BMO Capital | $15 → $13 | Maintains | Outperform |
| 09/12/2019 | 1671.7% | Wedbush | → $7 | Initiates Coverage On | → Outperform |
| 08/13/2019 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 03/22/2019 | 2937.21% | Cantor Fitzgerald | $18 → $12 | Maintains | Overweight |
| 01/17/2019 | 1924.8% | JP Morgan | $30 → $8 | Downgrades | Overweight → Neutral |
| 11/15/2018 | 10024.02% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 07/16/2018 | 7493.01% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 7999.22% | BMO Capital | → $32 | Initiates Coverage On | → Outperform |
Aptinyx Questions & Answers
The latest price target for Aptinyx (NASDAQ: APTX) was reported by HC Wainwright & Co. on August 26, 2022. The analyst firm set a price target for $1.00 expecting APTX to rise to within 12 months (a possible 153.10% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Aptinyx (NASDAQ: APTX) was provided by HC Wainwright & Co., and Aptinyx maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptinyx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptinyx was filed on August 26, 2022 so you should expect the next rating to be made available sometime around August 26, 2023.
While ratings are subjective and will change, the latest Aptinyx (APTX) rating was a maintained with a price target of $2.00 to $1.00. The current price Aptinyx (APTX) is trading at is $0.40, which is out of the analyst's predicted range.